Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STC-15 + toripalimab
- Development stage
- Unknown
- Lead developer
- STORM Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
STC-15 + toripalimab is an investigational combination therapy for advanced cancers, currently being evaluated in a Phase 1b/2 clinical trial. STC-15 is a first-in-class, small molecule inhibitor of methyltransferase-like 3 (METTL3), a key RNA methyltransferase enzyme involved in cellular reprogramming through RNA modification. Toripalimab (marketed as LOQTORZI) is a monoclonal antibody targeting programmed cell death protein 1 (PD-1) and functions as a checkpoint inhibitor to enhance antitumor immunity. This combination is under development for the treatment of locally advanced unresectable or metastatic cancers, including non-small cell lung cancer (NSCLC), melanoma, endometrial cancer, and head and neck squamous cell carcinoma (HNSCC). The trial aims to establish safety, tolerability, pharmacokinetics, and preliminary antitumor activity[1][2][3][5].
- Other names
- STC-15 + LOQTORZISTC-15 + toripalimab-tpzi
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)METTL3 (Methyltransferase-like protein 3)
Beyond the preview
Go deeper on STC-15 + toripalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STC-15 + toripalimab.